What are the opening hours?

Monday 9am - 6pm Tuesday 9am - 6pm Wednesday 9am - 6pm Thursday 9am - 6pm Friday 9am - 6pm

Tiberend Strategic Advisors, Inc.

Name: Tiberend Strategic Advisors, Inc.
Address: 35 W 35th Street Rm 1102, New York, NY, 10001, US
Telephone: (212) 827-0020
Price range: $$$$

Home
United States
New York, NY
Tiberend Strategic Advisors, Inc.

Tiberend Strategic Advisors, Inc. is a fully integrated strategic communications firm.

Founded in 1989, the firm’s mission is to provide expert corporate, investor, and product communications counsel to companies in the healthcare and life sciences. (TSAI) is a full service corporate communications firm specializing in the healthcare and life sciences industry. Founded in 1989, TSAI’s mission is to provide expert public and investor relations counsel to companies along the entire de

velopment lifecycle, from emerging, clinical-stage to publicly traded, revenue generating. In doing so, TSAI creates individualized platforms for companies to communicate their value proposition to those audiences that have the greatest influence on their growth and success - investors, industry stakeholders, customers and the media. Specialties
Our firm provides strategic corporate communications as it fits into an overall investor communications program, management counsel, corporate positioning, pre-IPO public relations programs and media outreach.

03/30/2021

Congratulations to the BridGene Biosciences management team.

Takeda has teamed up with BridGene Biosciences to discover small molecules against targets once thought to be undruggable. The five-program agreement, which is potentially worth more than $500 million, wraps up a busy month for deal-making at Takeda.

03/03/2021

Congratulations to KemPharm, Inc. (Nasdaq: KMPH) CEO Travis Mickle and his team on the FDA approval of AZSTARYS™, a once-daily product for the treatment of ADHD in patients age six years and older. AZSTARYS consists of serdexmethylphenidate, KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated with immediate-release d-MPH.

Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET CELEBRATION, Fla., March 02, 2021 (GLOBE NEWSWIRE)...

02/17/2021

http://www.globenewswire.com/news-release/2021/02/17/2177015/0/en/Salarius-Completes-Dose-Escalation-Stage-of-Phase-1-2-Clinical-Trial-in-Relapsed-and-Refractory-Ewing-Sarcoma-Patients-Initiates-Expansion-Stage-in-Ewing-and-Ewing-Related-Sarcoma-.html

Seclidemstat safety profile affirmed; Recommended Phase 2 dose established Demonstrated preliminary evidence of seclidemstat drug activity in subset of...

02/09/2021

https://www.globenewswire.com/news-release/2021/02/08/2171321/0/en/AzurRx-BioPharma-to-Present-at-BIO-CEO-Investor-Digital-Conference.html

DELRAY BEACH, Fla., Feb. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the...

02/03/2021

Codagenix, Inc. CEO J. Robert Coleman featured in S&P Global Market Intelligence where he discusses the company's vaccine candidate, which is a live-attenuated vaccine — a weakened form that will not cause disease — that can be administered through the nose.

Unlike the COVID-19 vaccines from Pfizer and Moderna, Codagenix's version is a live-attenuated vaccine — a weakened form that will not cause disease — that can be administered through the nose and does not require ultra-cold storage.

02/01/2021

https://www.prnewswire.com/news-releases/marizyme-inc-strengthens-senior-management-team-with-two-appointments-roger-schaller-evp-commercial-operations-and-amy-chandler-evp-regulatory-affairs-and-quality-management-systems-301218809.html?tc=eml_cleartime

/PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion...

01/28/2021

https://medcitynews.com/2021/01/startup-banks-on-immune-system-memory-to-tackle-cancer/

Loki Therapeutics is advancing research that leverages the immune system's ability to recall childhood vaccinations and direct it against cancer. The company's lead therapy candidate could enter phase 1 clinical trials this year.

01/28/2021

https://www.globenewswire.com/news-release/2021/01/27/2165069/0/en/KemPharm-Receives-FDA-Clearance-to-Initiate-KP879-Clinical-Program-for-the-Treatment-of-Stimulant-Use-Disorder.html

Financial Restructuring and Nasdaq Re-Listing Process Completed CELEBRATION, Fla., Jan. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a...

01/19/2021

https://www.prnewswire.com/news-releases/bioeclipse-initiates-enrollment-in-phase-1-dose-escalation-clinical-trial-for-crx100-at-honorhealth-research-institute-301210569.html

/PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing...

01/14/2021

https://www.globenewswire.com/news-release/2021/01/14/2158546/0/en/KemPharm-s-KP415-and-Serdexmethylphenidate-SDX-Prodrug-to-be-Featured-in-Multiple-Sessions-at-the-2021-APSARD-Virtual-Conference.html

Combination of Oral and Poster Presentations Scheduled for January 15, 2021 CELEBRATION, Fla., Jan. 14, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc....

01/14/2021

https://www.prnewswire.com/news-releases/marizyme-announces-approval-for-duragraft-in-india-301207922.html?tc=eml_cleartime

/PRNewswire/ -- Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion...

01/13/2021

http://www.globenewswire.com/news-release/2021/01/13/2157809/0/en/Salarius-Pharmaceuticals-Receives-Second-Installment-of-1-7-Million-in-Payments-from-the-Cancer-Prevention-and-Research-Institute-of-Texas.html

HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential...

Address

35 W 35th Street Rm 1102
New York, NY
10001

Opening Hours

Monday	9am - 6pm
Tuesday	9am - 6pm
Wednesday	9am - 6pm
Thursday	9am - 6pm
Friday	9am - 6pm

Telephone

(212) 827-0020

Website

http://www.tiberend.com/

Alerts

Be the first to know and let us send you an email when Tiberend Strategic Advisors, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Tiberend Strategic Advisors, Inc.:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Business
Claim ownership or report listing

Want your business to be the top-listed Advertising & Marketing Company in New York?

Tiberend Strategic Advisors, Inc.

03/30/2021

03/03/2021

02/17/2021

02/09/2021

02/03/2021

02/01/2021

01/28/2021

01/28/2021

01/19/2021

01/14/2021

01/14/2021

01/13/2021

Address

Opening Hours

Telephone

Website

Alerts

Contact The Business

Shortcuts

Share

Category